Inventor · disambiguated record
Kiel Lazarski
Also filed as: LAZARSKI KIEL
23 granted patents·13 pending applications·156 citations·filing 2017–2025
95Inventor score
Top patents by PatentIndex Score
36 records- 0197US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0297US10660968B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·32 cites·35 claims
- 0396US12209091B2Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancersHOFFMANN LA ROCHE·Filed 2020·Granted Jan 28, 2025·7 cites·30 claims
- 0496US11524949B2Degraders and Degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0596US10849982B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted Dec 1, 2020·43 cites·17 claims
- 0695US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 0795US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 0894US11708354B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2020·Granted Jul 25, 2023·3 cites·16 claims
- 0993US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 1093US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1193US11492358B1Macrocyclic indole derivativesBAYER AG·Filed 2021·Granted Nov 8, 2022·3 cites·18 claims
- 1292US10981932B2Macrocyclic indole derivativesBAYER AG·Filed 2017·Granted Apr 20, 2021·9 cites·17 claims
- 1390US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 1490US11891404B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2022·Granted Feb 6, 2024·1 cites·10 claims
- 1588US12152041B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2022·Granted Nov 26, 2024·1 cites·6 claims
- 1687US11440923B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2018·Granted Sep 13, 2022·3 cites·15 claims
- 1787US10882848B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2019·Granted Jan 5, 2021·3 cites·15 claims
- 1886US11478451B1Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Oct 25, 2022·3 cites·16 claims
- 1986US11401278B2Macrocyclic indole derivativesBROAD INST INC·Filed 2018·Granted Aug 2, 2022·3 cites·13 claims
- 2085US11447504B2Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Sep 20, 2022·3 cites·14 claims
- 2185US11286263B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2018·Granted Mar 29, 2022·3 cites·9 claims
- 2283US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2380US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 2480US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2579US12421220B2Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·26 claims
- 2679US2025382285A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2779US2025368631A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2863US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2963US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3062US2019076539A1Amine-linked c3-glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3156US2023233692A1Compounds for targeted degradation of retC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3251US2020308171A1Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moietyHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3351US2023002367A1Bifunctional compoundsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3451US2023024096A1Bifunctional compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3551US2020361930A1Bifunctional molecules that degrade egfrHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3643US2021253598A1Aryl annulated macrocyclic indole derivativesBAYER AG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kiel Lazarski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →